In this ODwire.org webinar, Melissa Barnett, OD and Susan Resnick, OD help us learn more about ptosis, including causes, diagnosis, treatment landscape, impact on patients, and opportunity for your practice.
Jason Bacharach, MD, introduces the first and only FDA-approved pharmacologic treatment for acquired blepharoptosis, RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, including its mechanism of action and clinical data.
There are 23 comments on this article. log in to join the discussion!